Last reviewed · How we verify

NCT05770076

Probiotic Lysate (Postbiotic and Metabiotic) Supplementation for Type 2 Diabetes Patients (DELI_Diab Study)

Completed NA Last updated 3 April 2024
What this trial tests

NA trial testing Probiotic lysate (postbiotic and metabiotic) in Obesity in 55 participants. Completed in 31 December 2023.

Timeline
1 February 2023
Primary endpoint
31 December 2023
31 December 2023

Quick facts

Lead sponsorBogomolets National Medical University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment55
Start date1 February 2023
Primary completion31 December 2023
Estimated completion31 December 2023
Sites4 locations across Ukraine

Drugs / interventions tested

Conditions studied

Sponsor

Bogomolets National Medical University

Who can join

Adults 18 to 70, any sex, with Obesity or Obesity, Abdominal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The current study aim was to conduct placebo-controlled randomize clinical trial to assess the short-term efficacy and safety of postbiotics as an adjunction to the standard anti-diabetic therapy on insulin resistance, glycemic control parameters, β-cells functional activity, anthropometric parameters and markers of a chronic systemic inflammatory response in type 2 diabetes patients. The study will include 3 periods. Screening period of up to 1 weeks to assess the eligibility to inclusion/exclusion criteria. Treatment period for 3 month where the participants will receive a twice daily oral dose of postbiotics (cell lysate and DNA fragments of the probiotic strain L. rhamnosus DV - NRRLB-68023) at the assigned dose of 100mg or placebo in capsules. During this period monthly phone contacts will be done for assessment of compliance and safety concerns. Follow-up period of up to 3 month.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

  1. A Comprehensive Overview of Postbiotics with a Special Focus on Discovery Techniques and Clinical Applications.
    Kumar A, Green KM, Rawat M. · · 2024 · cited 34× · PMID 39335866 · DOI 10.3390/foods13182937
  2. Effect of probiotics derivatives (postbiotics and metabiotics) on glycemic control in individuals with type 2 diabetes: a randomized clinical trial (DELI_Diab study).
    Savytska M, Baka O, Manzhalii E, Kyriienko D, et al · · 2026 · PMID 42158917 · DOI 10.3389/fendo.2026.1802045
  3. Incorporating Postbiotics into Intervention for Managing Obesity.
    Hijová E, Bertková I, Štofilová J. · · 2025 · PMID 40508171 · DOI 10.3390/ijms26115362

Verify or expand the search:

Other recruiting trials for Obesity

Currently open trials in the same condition.

Other Bogomolets National Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05770076.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing